ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees

FREMONT, CA , Jan. 03, 2024 (GLOBE NEWSWIRE) — via NewMediaWire  – ABVC BioPharma, Inc. (NASDAQ:ABVC) and its subsidiary BioLite, Inc. (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc. (“AiBtl”), as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment. AiBtl is a private company, and the share value is based on the terms of the agreement between the parties and the valuation report done by an independent third party.

Read more at globenewswire.com